Significant Ownership of CITADEL ADVISORS LLC

Signature - Title
/s/ Seth Levy - Seth Levy, Authorized Signatory
Location
Miami, FL
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by CITADEL ADVISORS LLC.

Follow Filing Activity

Follow CITADEL ADVISORS LLC and return when a new Schedule 13D/G filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Create free account and return here Already have an account? Sign in and return here

Significant Ownership of CITADEL ADVISORS LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
DBV Technologies S.A. Ordinary shares, nominal value EUR0.10 per share (the "Shares") 6.4% 9,194,107 Kenneth Griffin 07 Apr 2025
Sun Country Airlines Holdings, Inc. Common Stock, par value $0.01 per share (the "Shares") 6.1% 3,196,914 Kenneth Griffin 11 Feb 2025
Aardvark Therapeutics, Inc. Common Stock, par value $0.00001 per share (the "Shares") 5.6% 1,192,971 Kenneth Griffin 14 Feb 2025
ARVINAS, INC. Common stock, par value $0.001 per share (the "Shares") 5.1% 3,480,125 Kenneth Griffin 23 Jan 2025
Protara Therapeutics, Inc. Common Stock, $0.001 par value per share (the "Shares") 4.7% 1,627,734 Kenneth Griffin 31 Dec 2024
ACELYRIN, Inc. Common Stock, par value $0.00001 per share (the "Shares") 4.2% 4,218,748 Kenneth Griffin 31 Dec 2024
Terns Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share (the "Shares") 4.1% 3,465,307 Kenneth Griffin 31 Dec 2024
Korro Bio, Inc. Common Stock, par value $0.001 per share (the "Shares") 3.9% 369,733 Citadel Advisors LLC 31 Dec 2024
COMPASS Pathways plc Ordinary Shares, par value of GBP 0.008 per share (the "Shares"), each represented by one American Depositary Share 1.7% 1,166,576 Kenneth Griffin 31 Dec 2024
HAWAIIAN ELECTRIC INDUSTRIES INC Common Stock, Without Par Value (the "Shares") 0% 0 Citadel Advisors LLC 31 Dec 2024
Lyra Therapeutics, Inc. Common Stock, $0.001 par value per share (the "Shares") 0% 0 Citadel Advisors LLC 31 Dec 2024

Schedules 13D/G Reported by CITADEL ADVISORS LLC:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .